Merus (MRUS) News Today $47.37 -0.26 (-0.55%) Closing price 04:00 PM EasternExtended Trading$47.36 -0.01 (-0.02%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period TimesSquare Capital Management LLC Purchases 58,760 Shares of Merus (NASDAQ:MRUS)TimesSquare Capital Management LLC boosted its position in Merus (NASDAQ:MRUS - Free Report) by 21.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 331,195 shares of the biotechnology company's stock after purchasing an additional 58,760February 20 at 4:53 AM | marketbeat.comMerus’ petosemtamab granted Breakthrough Therapy designation by FDAFebruary 19 at 9:54 AM | markets.businessinsider.comMerus’s Breakthrough in HNSCC: Buy Rating Backed by FDA Support and Promising Trial DataFebruary 19 at 7:13 AM | tipranks.comMerus NV (MRUS) Receives Second Breakthrough Therapy Designation for Petosemtamab in Head and ...February 19 at 6:24 AM | gurufocus.comMerus (MRUS) Expected to Announce Quarterly Earnings on WednesdayMerus (NASDAQ:MRUS) will be releasing earnings before the market opens on Wednesday, February 26.February 19 at 4:28 AM | marketbeat.comInnate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatmentsFebruary 18 at 5:14 PM | msn.com7MRUS : Merus Shares Are Up Today: What's Going On?February 18 at 5:14 PM | benzinga.comPetosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinomaFebruary 18 at 8:00 AM | globenewswire.comMerus N.V.'s SWOT analysis: biotech firm's stock poised for growth amid clinical trialsFebruary 17, 2025 | msn.comMerus (NASDAQ:MRUS) Receives Average Rating of "Buy" from AnalystsMerus (NASDAQ:MRUS - Get Free Report) has been given a consensus recommendation of "Buy" by the sixteen brokerages that are presently covering the company, Marketbeat reports. Fourteen analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the comFebruary 16, 2025 | marketbeat.comMerus (NASDAQ:MRUS) Coverage Initiated by Analysts at Piper SandlerFebruary 15, 2025 | americanbankingnews.comPiper Sandler Initiates Coverage of Merus N.V. (MRUS) with Overweight RecommendationFebruary 13, 2025 | msn.comMerus initiated with an Overweight at Piper SandlerFebruary 13, 2025 | markets.businessinsider.comPiper Sandler sets $84 target on Merus stock, cites drug potentialFebruary 13, 2025 | msn.comMerus NV (MRUS) to Present at Citi's 2025 Virtual Oncology Leadership SummitFebruary 13, 2025 | gurufocus.comMerus (NASDAQ:MRUS) Coverage Initiated at Piper SandlerPiper Sandler started coverage on Merus in a report on Thursday. They issued an "overweight" rating and a $84.00 target price for the company.February 13, 2025 | marketbeat.comMerus to Present at Citi's 2025 Virtual Oncology Leadership SummitFebruary 13, 2025 | globenewswire.comAnalyst Recommends Buy for Merus Based on Promising Petosemtamab Developments and Revenue PotentialFebruary 13, 2025 | tipranks.comMerus (NASDAQ:MRUS) Given "Buy" Rating at GuggenheimGuggenheim reaffirmed a "buy" rating on shares of Merus in a research report on Wednesday.February 12, 2025 | marketbeat.comFY2024 Earnings Forecast for Merus Issued By Leerink PartnrsMerus (NASDAQ:MRUS - Free Report) - Investment analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for Merus in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now expects that the biotechnology company will post earnings of (February 10, 2025 | marketbeat.comWells Fargo sets $91 target on Merus stock, cites mCRC potentialFebruary 8, 2025 | msn.comMerus initiated with an Overweight at Wells FargoFebruary 8, 2025 | markets.businessinsider.comWells Fargo & Company Begins Coverage on Merus (NASDAQ:MRUS)Wells Fargo & Company started coverage on shares of Merus in a research note on Friday. They issued an "overweight" rating and a $91.00 target price for the company.February 7, 2025 | marketbeat.comQ1 Earnings Forecast for Merus Issued By Leerink PartnrsMerus (NASDAQ:MRUS - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Merus in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the biotechnology company will earn ($1.18) per shFebruary 7, 2025 | marketbeat.comNew England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive CancerFebruary 5, 2025 | globenewswire.comKBC Group NV Acquires 56,012 Shares of Merus (NASDAQ:MRUS)KBC Group NV increased its holdings in shares of Merus (NASDAQ:MRUS - Free Report) by 4,583.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,234 shares of the biotechnology company's stock afterFebruary 2, 2025 | marketbeat.comA deep dive into the Merus Adventure ParkJanuary 28, 2025 | msn.comMerus (NASDAQ:MRUS) Given Average Recommendation of "Buy" by BrokeragesShares of Merus (NASDAQ:MRUS - Get Free Report) have earned an average recommendation of "Buy" from the fourteen research firms that are currently covering the company, MarketBeat Ratings reports. Twelve analysts have rated the stock with a buy recommendation and two have given a strong buy recommeJanuary 22, 2025 | marketbeat.comMerus’s Promising Clinical Trials and Strategic Collaborations Highlight Attractive Investment PotentialJanuary 21, 2025 | markets.businessinsider.comTime To Upgrade Merus N.V. To A 'Buy' After The Recent SelloffJanuary 20, 2025 | seekingalpha.comMerus N.V. (MRUS): The Biotech Stock with Biggest Upside PotentialJanuary 17, 2025 | insidermonkey.comMerus (NASDAQ:MRUS) Short Interest Down 15.5% in DecemberMerus (NASDAQ:MRUS - Get Free Report) was the target of a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 8,260,000 shares, a drop of 15.5% from the December 15th total of 9,780,000 shares. Based on an average daily volume of 539,100 shares, the short-interest ratio is presently 15.3 days.January 17, 2025 | marketbeat.comCompanies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In GrowthJanuary 15, 2025 | finance.yahoo.comBank of America Securities Sticks to Its Buy Rating for Merus (MRUS)January 14, 2025 | markets.businessinsider.comWhat's Going On With Merus Stock Monday?January 13, 2025 | benzinga.comMerus N.V.: Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC ProgramsJanuary 13, 2025 | finanznachrichten.deBiohaven, Merus enter research pact and license agreement to develop three ADCsJanuary 13, 2025 | markets.businessinsider.comBiohaven enters multi-target collaboration with MerusJanuary 13, 2025 | markets.businessinsider.comMerus (NASDAQ:MRUS) Sees Unusually-High Trading Volume - What's Next?Merus (NASDAQ:MRUS) Sees Large Volume Increase - What's Next?January 13, 2025 | marketbeat.comBiohaven And Merus Collaborate To Develop Novel Bispecific Antibody Drug ConjugatesJanuary 13, 2025 | markets.businessinsider.comMerus NV (MRUS) and Biohaven Announce Strategic Collaboration on Bispecific Antibody Drug ConjugatesJanuary 12, 2025 | gurufocus.comMerus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC ProgramsJanuary 12, 2025 | gurufocus.comMerus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC ProgramsJanuary 12, 2025 | globenewswire.comMerus (NASDAQ:MRUS) Stock Price Up 5.1% - Here's What HappenedMerus (NASDAQ:MRUS) Trading Up 5.1% - What's Next?January 10, 2025 | marketbeat.comJim Cramer Says Merus (MRUS) Still ‘Very Speculative’January 7, 2025 | insidermonkey.comCanaccord Genuity Sticks to Its Buy Rating for Merus (MRUS)December 17, 2024 | markets.businessinsider.comMerus N.V.: Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRCDecember 17, 2024 | finanznachrichten.deMerus NV (MRUS) Initiates Phase 2 Trial for Petosemtamab in Metastatic Colorectal CancerDecember 16, 2024 | gurufocus.comMerus doses first patient in petosemtamab trialDecember 16, 2024 | tipranks.comMerus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRCDecember 16, 2024 | globenewswire.com Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address MRUS Media Mentions By Week MRUS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRUS News Sentiment▼0.620.60▲Average Medical News Sentiment MRUS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRUS Articles This Week▼115▲MRUS Articles Average Week Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Vaxcyte News Today Sarepta Therapeutics News Today Qiagen News Today Ascendis Pharma A/S News Today Roivant Sciences News Today Revolution Medicines News Today Legend Biotech News Today BridgeBio Pharma News Today Axsome Therapeutics News Today Blueprint Medicines News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRUS) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
